iCAD’s Breast AI Platform Earns U.S. Department of Defense Authorization to Operate

January 24, 2022
Category: Press Releases

Leading-edge breast cancer detection platform meets stringent U.S. government security thresholds required for use across military healthcare facilities

 

NASHUA, N.H. – January 24, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Company’s breast artificial intelligence (AI) platform was granted an Authorization to Ope... Continue reading

Tags: press releases

iCAD Announces the Appointment of New Members to its Board of Directors

January 11, 2022
Category: Press Releases

Dana Brown and Timothy Norris Irish offer extensive experience in technology, women’s breast health and unique global perspectives


NASHUA, N.H., January 11, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, announced today it has appointed Dana Brown and Timothy Norris Irish as new independe... Continue reading

Tags: press releases

iCAD Announces Estimated Q4 and Fiscal Year 2021 Revenues

January 04, 2022
Category: Press Releases

Company expects preliminary estimated Q4 2021 revenues to be between .8-.0 million


NASHUA, N.H., January 4, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, reported select preliminary, unaudited financial results for the fourth quarter and full year of 2021. Based on preliminary, unaudited financial inf... Continue reading

Tags: press releases

iCAD to Participate at the 11th Annual LifeSci Partners Virtual Corporate Access Event

December 23, 2021
Category: Press Releases

Company’s President and incoming CEO to participate in a panel discussion titled “Med Tech / Digital Tools: What's the Mindset for 2022?” on January 5, 2022 at 2:00 pm ET


NASHUA, N.H., Dec. 23, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will attend the 11th Annual LifeSci Partners Corporate Access Event, being held virtually from January 5th to 7th, 2022.

Stacey Stevens, President and incoming CEO of iCAD, wil... Continue reading

Tags: press releases

First Recurrent Glioblastoma Tumor is Treated with Xoft Brain IORT in the United States

December 15, 2021
Category: iNFORMED - Blog

Treatment marks initiation of international multicenter trial evaluating targeted radiation therapy and bevacizumab for the treatment of the most common and aggressive type of malignant brain tumor

 

Intriguing research supporting novel therapy approach recently published in peer-reviewed journal, Surgical Neurology International 

 ... Continue reading

Tags: iCAD Xoft Brain IORT
12-14-2021-brain-press-release-banner-660x360.jpg

First Recurrent Glioblastoma Tumor is Treated with Xoft Brain IORT in the United States

December 14, 2021
Category: Press Releases

Treatment marks initiation of international multicenter trial evaluating targeted radiation therapy and bevacizumab for the treatment of the most common and aggressive type of malignant brain tumor

 

Intriguing research supporting novel therapy approach recently published in peer-reviewed journal, Surgical Neurology International

Continue reading

Tags: press releases

iCAD to Participate at the Imagine AI + Healthcare Investor Summit

December 06, 2021
Category: Press Releases

NASHUA, N.H., Dec. 06, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Stacey Stevens, President and incoming Chief Executive Officer, will present a corporate overview at Oppenheimer’s Imagine AI + Healthcare Investor Summit being hosted by Oppenheimer in partnership with the Alliance for AI in Healthcare (AAIH).


Oppenheimer’s Imagine AI + Healthcare Investor Summit
Date:        Tuesday, December... Continue reading

Tags: press releases

iCAD Announces CEO Transition

December 06, 2021
Category: Press Releases

Stacey Stevens Appointed as President and CEO and will Join the Board of Directors in 2022, Michael Klein to remain Chairman of iCAD Board

 

NASHUA, N.H. – December 6, 2021 –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its Board of Directors appointed Stacey Stevens as iCAD’s President and Chief Executive Off... Continue reading

Tags: press releases

Arterys Signs Global Distribution Agreement With iCAD, Inc. to Launch Its New Breast AI SaaS Solution

November 30, 2021
Category: Press Releases

Partnership will expand worldwide access to iCAD’s full suite of breast health solutions on Arterys’ fully cloud-based SaaS platform

  

SAN FRANCISCO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Arterys, the world's leading vendor-neutral AI platform, today announced it signed a global distribution agreement with iCAD, a global medical technology leader providing innovative cancer detection and therapy solutions. This partnership will expand access to iCA... Continue reading

Tags: press releases

iCAD Announces Compelling New and Real-World Data Demonstrating the Value of ProFound AI to be Presented at RSNA 2021

November 29, 2021
Category: Press Releases

World’s first FDA cleared AI breast cancer detection software to be highlighted in three scientific presentations at largest radiological meeting in the world

 

iCAD’s innovative breast health solutions, including ProFound AI Risk and PowerLook Density Assessment, to be showcased during the meeting

 

NASHUA, N.H. – November 29, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and th... Continue reading

Tags: press releases

iCAD to Participate in the 12th Annual Craig-Hallum Alpha Select Conference

November 11, 2021
Category: Press Releases

NASHUA, N.H., Nov. 11, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will participate in the 12th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 16, 2021, starting at 9:00 AM ET.

Management will be available to host virtual one-on-one meetings with investors who are registered to attend the conference. For more information, please visit Craig-Hallum.com.


About iCAD, Inc.
Headquartered in Nashua, N... Continue reading

Tags: press releases

iCAD to Host 2nd Annual Virtual Investor Webinar on Company’s Innovative Solutions for Cancer Detection and Treatment

November 11, 2021
Category: Press Releases

Leading clinical and administrative experts to discuss how leveraging iCAD’s Breast Health Solutions and the Xoft System can enhance clinical efficiency and improve outcomes for patients

 

Webinar taking place on Thursday, November 18 from 3:00 to 4:30 PM ET

 

NASHUA, N.H. – November 11, 2021 –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing... Continue reading

Tags: press releases

iCAD Reports Financial Results for the Quarter Ended September 30, 2021

November 09, 2021
Category: Press Releases

- Third Quarter Revenues of .4 Million Represented 20% Sequential Quarter Growth over the Second Quarter of 2021, Driven by 26% Growth in Detection Revenue and 10% Growth in Therapy Revenue -


- Third Quarter 2021 Revenues Represented 31% Growth Compared to the Third Quarter 2020 -


- Improving Enterprise Sales in the Third Quarter of 2021 Resulted in a 41% Sequential Quarter Increase in Detection Product Revenues -

-... Continue reading

Tags: press releases

iCAD to Report Third Quarter 2021 Financial Results on Tuesday, November 9

October 26, 2021
Category: Press Releases

NASHUA, N.H., Oct. 26, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the third quarter ended September 30, 2021, after the market close, and host a conference call at 4:30pm Eastern Time on Tuesday, November 9.


Tuesday, November 9th at 4:30pm ET

Domestic:

855-327-6837

... Continue reading

Tags: press releases

iCAD Unveils Next Generation Technologies at Journées Francophones de Radiologie

October 12, 2021
Category: iNFORMED - Blog

Leading-edge AI solution for 2D mammography enhances cancer detection performance for clinicians, with improved sensitivity, specificity, and processing times over previous versions

 

Latest generation of ProFound AI Risk, now available for digital breast tomosynthesis, provides an accurate, short-term breast cancer risk estimation for women, based only on a screening mammogram

 

iCAD will unveil the latest generation of ProFound AI® f... Continue reading

Tags: 3D Mammography Artificial Intelligence Breast Cancer Detection Breast Tomosynthesis Software Technology
ProFound_AI_for_2D_Mammography_Blog_Image.jpg

iCAD Unveils Next Generation Technologies at Journées Francophones de Radiologie (October 8-11, Paris, France)

October 07, 2021
Category: Press Releases

Leading-edge AI solution for 2D mammography enhances cancer detection performance for clinicians, with improved sensitivity, specificity, and processing times over previous versions

 

Latest generation of ProFound AI Risk, now available for digital breast tomosynthesis, provides an accurate, short-term breast cancer risk estimation for women, based only on a screening mammogram

 

NASHUA, N.H. and PARIS – October 7, 2021 - iCAD, Inc... Continue reading

Tags: press releases

iCAD Releases Next Generation PowerLook Density Assessment Solution

October 06, 2021
Category: iNFORMED - Blog

Dense breasts can make it challenging to detect breast cancer during annual screenings, as overlapping tissue can hide or mimic breast cancer, even with digital breast tomosynthesis (DBT) exams. Breast density assessment has traditionally been determined by the radiologist’s visual assessment, but studies show that these can vary, and clinicians may even disagree with their own assessment year to year.[1] This can be confusing for patients, lead to unnecessary additional imaging, and increase patient and facility costs.

 

Continue reading

Tags: 3D Mammography Artificial Intelligence Breast Cancer Detection Breast Tomosynthesis Software Technology
Density_Blog_Image-2021.jpg

Next Generation of ProFound AI Risk Offers Greater Accuracy and Ethnically Inclusive Precision Screening

September 30, 2021
Category: iNFORMED - Blog

iCAD, Inc. recently launched ProFound AI® Risk for digital breast tomosynthesis (DBT), or 3D mammography, the world’s first commercially available clinical decision support tool that provides an accurate[1],[2] short-term breast cancer risk estimation that is truly personalized for each woman, based only on a 2D or 3D mammogram. The latest version of this software offers improved accuracy and enhanced functionality compared to previous versions.

 

“ProFound AI Risk has... Continue reading

Tags: 3D Mammography Artificial Intelligence Breast Cancer Detection Breast Tomosynthesis Software Technology
PFAI_Risk_for_DBT_Blog_Image_-_2.jpg

iCAD Launches Revolutionary Short-term Personalized Risk Assessment Solution for 3D Mammography

September 29, 2021
Category: Press Releases

Latest generation of ProFound AI Risk offers greater accuracy and ethnically inclusive precision screening

 

Technology provides critical, risk-adaptive solutions for clinicians facing complex screening challenges presented by the COVID-19 pandemic

 

NASHUA, N.H. – September 29, 2021 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI® Risk for digital breast tomosynthesis... Continue reading

Tags: press releases

ImageCare Centers Unveils PINK Better Mammo Service, Featuring Profound AI®, the World’s First FDA Cleared Artificial Intelligence Solution for 3D Mammography

September 16, 2021
Category: iNFORMED - Blog

ImageCare Centers recently announced it will adopt ProFound AI® for Digital Breast Tomosynthesis (DBT) throughout all of ImageCare’s mammography centers this October as part of its “PINK Better Mammo” service. ProFound AI® was the first artificial intelligence (AI) software for DBT, or 3D mammography, to be FDA cleared; the software is clinically proven to improve accuracy and efficiency for radiologists reading mammography.[i]

Continue reading

Tags: 3D Mammography Artificial Intelligence Breast Cancer Detection Breast Tomosynthesis Software Technology
ImageCare_Centers_1.jpg

© iCAD Inc.  All rights reserved.  iCAD, the iCAD logo, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.

Facebook icon Twitter icon LinkedIn icon